All practice questions

Question 4501Question →

A 72-year-old man is evaluated in the hospital for decreased urine output. He was admitted 3 days ago for an acute exacerbation of heart failure with reduced ejection fraction. His treatment regimen includes intravenous furosemide, lisinopril, carvedilol, and spironolactone. His weight has decreased by 4 kg (8.8 lb) since admission, and his peripheral edema has significantly improved. However, his urine output over the last 12 hours has been only 250 mL.

Vitals:
Blood pressure: 102/60 mm Hg
Heart rate: 94/min

Laboratory results from today:
Serum:
Sodium: 135 mEq/L
Potassium: 4.8 mEq/L
Chloride: 98 mEq/L
Bicarbonate: 28 mEq/L
Blood urea nitrogen: 80 mg/dL
Creatinine: 2.4 mg/dL

Urine:
Sodium: 75 mEq/L
Creatinine: 120 mg/dL
Urea nitrogen: 600 mg/dL

Based on the laboratory findings, what is this patient's calculated fractional excretion of urea (expressed as a percentage)?

Show answer & explanation

Answer: 15

Answer

15

The correct calculation uses the formula

FeUrea = \frac{\text{Urine Urea Nitrogen} \times \text{Serum Creatinine}}{\text{Serum BUN} \times \text{Urine Creatinine}} \times 100

. Plugging in the provided values gives

\frac{600 \times 2.4}{80 \times 120} \times 100

, which simplifies to

\frac{1440}{9600} \times 100 = 15\%

. In a patient receiving loop diuretics (like furosemide), Fractional Excretion of Sodium (FeNa) is falsely elevated due to diuretic-induced natriuresis. Urea handling in the proximal tubule is unaffected by loop diuretics, making FeUrea a much more reliable indicator of prerenal azotemia. A value below

35\%

supports the diagnosis of prerenal acute kidney injury due to aggressive over-diuresis.

Step-by-Step Solution

1

Identify the clinical context and indication for calculating FeUrea.

The patient has AKI while on furosemide, making FeNa unreliable. FeUrea is indicated.

Loop diuretics inhibit Na+ reabsorption, falsely elevating FeNa even in prerenal states. Urea is reabsorbed proximally, independent of loop diuretics.

2

Recall the Fractional Excretion of Urea formula.

FeUrea = \frac{U_{Urea} \times P_{Cr}}{P_{BUN} \times U_{Cr}} \times 100

Fractional excretion compares the clearance of a substance (urea) to the clearance of creatinine.

3

Extract the correct values from the laboratory panel.

U_{Urea}

= 600 mg/dL,

P_{Cr}

= 2.4 mg/dL,

P_{BUN}

= 80 mg/dL,

U_{Cr}

= 120 mg/dL

Accurate variable selection is required; distractors like Urine Na and Serum Na must be ignored.

4

Execute the calculation.

\frac{600 \times 2.4}{80 \times 120} \times 100 = 15\%

Mathematical derivation of the fractional excretion percentage.

Key Concept

Fractional Excretion of Urea (FeUrea) is used to differentiate prerenal AKI from acute tubular necrosis in patients on diuretic therapy, where FeNa is often falsely elevated. A FeUrea < 35% indicates a prerenal etiology.

Question 4502Question →

Match each clinical and laboratory presentation with its most likely underlying pathophysiologic mechanism.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Patient 1 matches with IgG autoantibodies (ITP). Patient 2 matches with ADAMTS13 deficiency (TTP). Patient 3 matches with systemic activation of the coagulation cascade (DIC). Patient 4 matches with autoantibodies against phospholipid-binding proteins (Antiphospholipid Syndrome).

Each clinical vignette provides pathognomonic laboratory findings that differentiate these hematologic disorders. ITP is defined by isolated autoantibody-mediated platelet destruction. TTP is driven by uncleaved von Willebrand factor multimers creating platelet microthrombi (normal coags, schistocytes). DIC involves systemic factor consumption (prolonged coags). Lupus anticoagulant acts as an inhibitor, artificially prolonging aPTT while causing thrombosis.

Step-by-Step Solution

1

Analyze the first presentation (isolated severe thrombocytopenia with normal coagulation times and large platelets).

Identified as Immune Thrombocytopenic Purpura (ITP).

The absence of schistocytes rules out microangiopathic processes, and normal PT/aPTT rules out consumptive coagulopathies.

2

Analyze the second presentation (thrombocytopenia, schistocytes, renal injury, neurologic symptoms, and normal coagulation times).

Identified as Thrombotic Thrombocytopenic Purpura (TTP).

The presence of microangiopathic hemolytic anemia with normal coagulation studies points strictly to ADAMTS13 deficiency causing platelet-rich microthrombi.

3

Analyze the third presentation (bleeding diathesis following obstetric complication, thrombocytopenia, prolonged PT/aPTT, and elevated D-dimer).

Identified as Disseminated Intravascular Coagulation (DIC).

Prolongation of both PT and aPTT alongside thrombocytopenia indicates systemic consumption of both coagulation factors and platelets.

4

Analyze the fourth presentation (venous thrombosis with isolated, non-correcting prolonged aPTT).

Identified as Antiphospholipid Syndrome (specifically lupus anticoagulant).

Failure of the aPTT to correct during a mixing study confirms the presence of an inhibitor (rather than a factor deficiency) which paradoxically causes in vivo thrombosis.

Key Concept

Pathophysiology and laboratory differentiation of thrombocytopenia and coagulation disorders

Question 4503Question →

Match each patient's clinical presentation with the most likely rheumatologic diagnosis.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Polyarteritis nodosa matches with the hepatitis B patient; Eosinophilic granulomatosis with polyangiitis matches with the asthmatic patient with eosinophilia; Granulomatosis with polyangiitis matches with the PR3-ANCA positive patient with respiratory and renal involvement; Giant cell arteritis matches with the older patient with jaw claudication and visual symptoms.

Each diagnosis is established by recognizing specific syndromic clusters: PAN is associated with Hepatitis B and mesenteric/neurologic involvement; EGPA features asthma and eosinophilia; GPA features upper/lower airway necrosis and glomerulonephritis; GCA features cranial symptoms in older adults.

Step-by-Step Solution

1

Analyze each patient's demographic profile, comorbidities, and pattern of organ involvement.

Identified distinct syndromic clusters for each patient (e.g., asthma/eosinophilia vs. upper/lower respiratory/renal).

Vasculitides are diagnosed clinically by recognizing specific patterns of organ involvement and associated demographic/serologic risk factors.

2

Correlate the identified syndromic clusters with the known pathophysiologic features of specific systemic vasculitides.

Matched each clinical vignette to the corresponding small, medium, or large vessel vasculitis.

Accurate diagnosis dictates the appropriate immunosuppressive therapy and monitoring strategy.

Key Concept

Diagnosis and clinical recognition of systemic vasculitides

Question 4504Question →

A 54-year-old man is evaluated in the intensive care unit for a new-onset fever. He was admitted 6 days ago following a severe motor vehicle collision that resulted in multiple rib fractures and a pulmonary contusion. He required endotracheal intubation and mechanical ventilation on the day of admission. Over the past 24 hours, he has developed a temperature of $38.9^\circ\text{C}$ ( $102.0^\circ\text{F}$ ) and requires an increasing fraction of inspired oxygen ( $\text{FiO}_2$ ) and positive end-expiratory pressure. Endotracheal suctioning yields thick, purulent secretions. A chest radiograph reveals a new right lower lobe consolidation. His leukocyte count is $16,500/\text{mm}^3$ . A bronchoalveolar lavage is performed, and he is started on empiric intravenous vancomycin and cefepime. Two days later, his oxygenation has stabilized. The bronchoalveolar lavage fluid cultures grow $> 10^4 \text{ CFU/mL}$ of *Pseudomonas aeruginosa*. The isolate is susceptible to cefepime, piperacillin-tazobactam, and meropenem. No other organisms are isolated. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

Discontinue vancomycin and continue intravenous cefepime

Continue intravenous vancomycin and cefepime

Discontinue vancomycin and replace cefepime with intravenous meropenem

Discontinue vancomycin and add intravenous ciprofloxacin to the current regimen

Transition to intravenous piperacillin-tazobactam and linezolid

Show answer & explanation

Answer: Discontinue vancomycin and continue intravenous cefepime

Answer

Discontinue vancomycin and continue intravenous cefepime.

The correct response demonstrates appropriate antibiotic stewardship by de-escalating empiric broad-spectrum therapy once culture data are available. The patient has ventilator-associated pneumonia (VAP) and was started on empiric vancomycin (for MRSA) and cefepime (for Pseudomonas and other Gram-negatives). Bronchoalveolar lavage cultures definitively isolated *Pseudomonas aeruginosa* susceptible to cefepime, without any growth of MRSA. Therefore, vancomycin should be discontinued to reduce the risk of adverse effects (e.g., acute kidney injury), and cefepime should be continued as targeted, single-agent therapy.

Step-by-Step Solution

1

Evaluate the clinical presentation and initial management.

The patient developed ventilator-associated pneumonia (VAP) and was appropriately started on empiric broad-spectrum coverage for MRSA (vancomycin) and antipseudomonal beta-lactam (cefepime).

Empiric VAP therapy must cover the most common, high-risk nosocomial pathogens based on local antibiograms and patient risk factors.

2

Analyze the culture and susceptibility data.

Cultures grew only *Pseudomonas aeruginosa*, which is fully susceptible to the currently administered cefepime. Notably, no MRSA or other Gram-positive pathogens were isolated.

Definitive antibiotic therapy relies on pathogen identification and susceptibility testing to optimize efficacy and minimize collateral damage.

3

Apply the principles of antibiotic stewardship to modify therapy.

Vancomycin should be discontinued to eliminate unnecessary MRSA coverage, and cefepime can be continued as targeted monotherapy.

De-escalation of empiric broad-spectrum antibiotics to narrower, targeted agents prevents the development of multidrug-resistant organisms and reduces medication-related adverse effects (such as vancomycin-induced acute kidney injury).

Key Concept

In the management of ventilator-associated pneumonia (VAP), empiric broad-spectrum antibiotics should be de-escalated to targeted monotherapy as soon as culture and susceptibility results are available and demonstrate a susceptible pathogen.

Question 4505Question →

An 81-year-old female resident of a skilled nursing facility is currently recovering in the intensive care unit after presenting three days prior with severe distributive shock secondary to a catheter-associated urinary tract infection. On admission, she was hypotensive and tachycardic, and empiric antimicrobial therapy was initiated with intravenous vancomycin and piperacillin-tazobactam. Today, she is hemodynamically stable, off vasopressor support, and her temperature has normalized to 37.1°C (98.8°F). The indwelling urinary catheter was removed on the first day. Both the admission urine and blood cultures have grown *Escherichia coli*. The susceptibility report for the bloodstream isolate is provided below:

Antimicrobial Agent	Susceptibility
Ampicillin	Resistant
Ceftriaxone	Resistant
Cefepime	Resistant
Piperacillin-tazobactam	Susceptible
Gentamicin	Susceptible
Meropenem	Susceptible

Based on the culture results and the patient's current clinical status, which of the following is the most appropriate definitive pharmacotherapy?

Monotherapy with intravenous piperacillin-tazobactam

Monotherapy with oral fosfomycin

Monotherapy with intravenous meropenem

Monotherapy with intravenous gentamicin

Combination therapy with intravenous piperacillin-tazobactam and gentamicin

Show answer & explanation

Answer: Monotherapy with intravenous meropenem

Answer

Monotherapy with intravenous meropenem

The patient has an Escherichia coli bloodstream infection with a classic resistance pattern for an Extended-Spectrum Beta-Lactamase (ESBL) producer, evidenced by resistance to ampicillin and advanced-generation cephalosporins (ceftriaxone, cefepime). For ESBL bacteremia, carbapenems (such as meropenem, imipenem, or ertapenem) are the definitive drug of choice. Although piperacillin-tazobactam frequently tests as susceptible in vitro (due to the tazobactam component inhibiting the ESBL enzyme), robust randomized controlled data (such as the MERINO trial) have clearly demonstrated that definitive therapy with piperacillin-tazobactam results in significantly higher 30-day mortality and clinical failure compared to carbapenems in bloodstream infections. Therefore, despite the patient's initial clinical improvement on empiric therapy, the regimen must be escalated to a carbapenem to ensure definitive cure.

Step-by-Step Solution

1

Analyze the antimicrobial susceptibility report.

Identify resistance to 3rd-generation cephalosporins (ceftriaxone) but susceptibility to carbapenems, indicative of an Extended-Spectrum Beta-Lactamase (ESBL) producing E. coli.

Correct identification of the specific resistance mechanism is mandatory to evaluate true in vivo efficacy versus in vitro testing artifacts.

2

Assess the anatomical site and severity of the infection.

The patient has a confirmed bloodstream infection (bacteremia) originating from the urinary tract.

The efficacy of certain antibiotics varies drastically based on whether the infection is localized (e.g., cystitis) or systemic (e.g., bacteremia).

3

Select the definitive antimicrobial agent.

Transition from empiric piperacillin-tazobactam to a targeted carbapenem (meropenem).

Current IDSA guidelines mandate carbapenems for ESBL bacteremia due to established superiority in mortality outcomes over piperacillin-tazobactam.

Key Concept

Carbapenems are the definitive treatment of choice for bloodstream infections caused by ESBL-producing organisms; piperacillin-tazobactam should be avoided in bacteremia even if reported as susceptible in vitro.

Question 4506Question →

A 45-year-old man presents to the clinic with complaints of progressive enlargement of his hands and feet over the past two years, requiring him to buy larger shoes and a new wedding ring. He also reports excessive sweating and recently began snoring loudly at night. On physical examination, he has a prominent jaw, an enlarged nose, and macroglossia. You suspect a growth hormone-secreting pituitary adenoma. Arrange the following steps in the most appropriate chronological sequence for the diagnosis and initial management of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Measurement of IGF-1, 2) Oral glucose suppression test with GH measurement, 3) MRI of the pituitary gland, and 4) Evaluation for transsphenoidal surgery.

The standard diagnostic and management algorithm for suspected acromegaly proceeds in a stepwise fashion from screening to confirmation to localization to treatment. Initial screening is performed with an IGF-1 level, which integrates pulsatile growth hormone secretion over time. If elevated, the diagnosis must be biochemically confirmed using an oral glucose suppression test. Once biochemical excess is definitively proven, a pituitary MRI is obtained to localize the source (typically a somatotroph adenoma). Finally, transsphenoidal surgical resection is the first-line treatment for the vast majority of cases.

Step-by-Step Solution

1

Identify the suspected diagnosis based on the clinical presentation.

The patient's enlarging hands and feet, coarse facial features, and macroglossia strongly suggest acromegaly.

Recognizing the clinical syndrome determines the correct diagnostic pathway.

2

Determine the best initial screening test.

Serum IGF-1 level is selected as the first step.

Growth hormone is secreted in a pulsatile manner, making random measurements unreliable. IGF-1 provides a stable indicator of overall growth hormone excess.

3

Determine the confirmatory diagnostic test.

An oral glucose suppression test is placed second.

Biochemical confirmation of autonomous growth hormone secretion is required before imaging. Normal physiology involves suppression of growth hormone by a glucose load.

4

Select the appropriate imaging modality.

Pituitary MRI is placed third.

Imaging must only follow biochemical confirmation to avoid the misattribution of symptoms to incidental, nonfunctioning pituitary microadenomas.

5

Determine the definitive initial management.

Surgical evaluation is placed last.

Once the adenoma is functionally and anatomically characterized, transsphenoidal surgery is the definitive primary therapy.

Key Concept

The diagnostic workup for acromegaly requires sequential biochemical testing (screening with IGF-1, followed by confirmatory oral glucose suppression testing) prior to anatomical localization with a pituitary MRI.

Question 4507Question →

Match each specific circulating autoantibody with the endocrine disorder it is most classically used to diagnose or evaluate.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Thyroid-stimulating immunoglobulins match with Graves disease; Anti-thyroid peroxidase antibodies match with Hashimoto thyroiditis; Anti-glutamic acid decarboxylase antibodies match with Type 1 diabetes mellitus; Anti-21-hydroxylase antibodies match with Primary adrenal insufficiency.

Each circulating autoantibody specifically corresponds to the pathogenesis of a distinct endocrine disorder. The pairings correctly link the antibody targets to their respective clinical syndromes.

Step-by-Step Solution

1

Identify the autoantibody responsible for stimulating the thyroid gland.

Thyroid-stimulating immunoglobulins (TSI) are matched with Graves disease.

These antibodies mimic TSH, leading to unregulated hormone production and clinical hyperthyroidism.

2

Identify the primary autoantibody associated with autoimmune hypothyroidism.

Anti-thyroid peroxidase (anti-TPO) antibodies are matched with Hashimoto thyroiditis.

Anti-TPO antibodies indicate immune-mediated thyroid destruction resulting in eventual hypothyroidism.

3

Identify the autoantibody associated with pancreatic beta-cell destruction.

Anti-glutamic acid decarboxylase (anti-GAD65) antibodies are matched with Type 1 diabetes mellitus.

GAD65 is a major autoantigen in the immune destruction of insulin-producing beta cells.

4

Identify the autoantibody linked to autoimmune destruction of the adrenal cortex.

Anti-21-hydroxylase antibodies are matched with Primary adrenal insufficiency.

The 21-hydroxylase enzyme is the primary target in autoimmune adrenalitis (Addison disease).

Key Concept

Many major endocrine disorders are mediated by specific autoimmune processes, which can be clinically identified through distinct circulating autoantibodies.

Question 4508Question →

Match each presentation of calcium, phosphorus, and parathyroid hormone (PTH) laboratory abnormalities with its most likely underlying pathophysiologic diagnosis.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Primary hyperparathyroidism corresponds to high calcium/PTH and low phosphorus. Hypoparathyroidism matches low calcium/PTH and high phosphorus. Pseudohypoparathyroidism presents with low calcium, high phosphorus, high PTH, and normal creatinine. Malignancy (PTHrP) shows high calcium, low PTH, and low phosphorus. CKD shows low calcium, high phosphorus, high PTH, and elevated creatinine.

Each laboratory profile uniquely identifies a specific derangement in the calcium-PTH-vitamin D axis. Primary defects in PTH secretion cause calcium and PTH to move in the same direction. Secondary responses or ectopic mimics cause them to move in opposite directions. Phosphorus typically moves opposite to functional PTH activity on the kidney, except when overt renal failure physically prevents its excretion.

Step-by-Step Solution

1

Evaluate serum calcium and PTH directionality to determine primary versus secondary derangements.

If both move in the same direction, the defect is likely primary to the parathyroid gland (e.g., primary hyperparathyroidism or hypoparathyroidism). If they move in opposite directions, the parathyroid is responding appropriately to a systemic issue.

PTH regulates calcium; normally, low calcium stimulates PTH, and high calcium suppresses PTH.

2

Analyze serum phosphorus levels in relation to PTH.

PTH promotes phosphaturia. Elevated PTH should normally cause low phosphorus (as seen in primary hyperparathyroidism). If PTH is high but phosphorus is also high, suspect renal failure (CKD) or renal resistance to PTH (pseudohypoparathyroidism).

Kidneys are the primary site of phosphate regulation by PTH.

3

Differentiate between pseudohypoparathyroidism and secondary hyperparathyroidism.

Check renal function (creatinine). Elevated creatinine points to CKD, whereas normal creatinine points to pseudohypoparathyroidism.

CKD causes phosphate retention due to loss of glomerular filtration, whereas pseudohypoparathyroidism involves a specific receptor/signaling defect with normal overall renal filtration capacity.

Key Concept

Diagnosis of calcium and parathyroid disorders relies on recognizing the normal physiological feedback loops between serum calcium, serum phosphorus, intact parathyroid hormone, and renal function.

Question 4509Question →

Match each constellation of laboratory findings to the most likely underlying pathophysiologic diagnosis.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The laboratory patterns uniquely correspond to autonomous PTH production (Primary hyperparathyroidism), renal failure with impaired vitamin D activation (CKD-MBD), ectopic PTHrP production (Humoral hypercalcemia of malignancy), altered calcium sensing (Familial hypocalciuric hypercalcemia), and deficient substrate for active vitamin D (Severe nutritional vitamin D deficiency).

Each specific combination of serum calcium, phosphorus, PTH, and supplementary markers uniquely identifies the locus of pathology in calcium homeostasis. High calcium with high PTH and hypercalciuria is the hallmark of primary hyperparathyroidism. Conversely, high calcium with high PTH but hypocalciuria defines FHH. High calcium with suppressed PTH but elevated PTHrP confirms HHM. In hypocalcemic states, a high phosphorus indicates renal failure (CKD-MBD), whereas a low phosphorus with low 25-hydroxyvitamin D confirms nutritional vitamin D deficiency.

Step-by-Step Solution

1

Evaluate the serum calcium and intact PTH levels to categorize the primary disturbance.

Identifies PTH-dependent hypercalcemia (high Ca, high PTH), PTH-independent hypercalcemia (high Ca, low PTH), or secondary hyperparathyroidism (low/normal Ca, high PTH).

This fundamental division narrows the differential diagnosis immediately.

2

Analyze phosphorus levels in the context of the PTH-calcium axis.

Low phosphorus with high PTH confirms PTH-mediated phosphate wasting (Primary hyperparathyroidism, Vitamin D deficiency). High phosphorus with high PTH suggests impaired renal excretion (CKD-MBD).

Phosphorus homeostasis differentiates primary renal failure from isolated PTH or Vitamin D abnormalities.

3

Utilize specific secondary markers (24-hour urine calcium, PTHrP, 25-OH Vitamin D) to confirm the exact etiology.

Differentiates Primary hyperparathyroidism (high urine Ca) from FHH (low urine Ca); confirms HHM via PTHrP; and distinguishes Vitamin D deficiency from CKD.

These specific markers isolate the pathophysiological root cause when the primary calcium-PTH axis shows similar patterns.

Key Concept

Interpretation of the calcium, phosphorus, parathyroid hormone, and vitamin D axes to diagnose specific metabolic bone and mineral disorders.

Question 4510Question →

Match the following glomerular diseases with their classic renal biopsy or immunofluorescence findings.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Minimal change disease pairs with podocyte effacement; Membranous nephropathy pairs with subepithelial 'spike and dome' deposits; IgA nephropathy pairs with mesangial immune complex deposits; and Goodpasture syndrome pairs with linear immunoglobulin deposition.

Each glomerular disease has a pathognomonic finding on biopsy. Minimal change disease requires electron microscopy to see podocyte effacement. Membranous nephropathy shows subepithelial 'spike and dome' deposits. IgA nephropathy localizes to the mesangium. Goodpasture syndrome is distinguished by linear anti-GBM antibody deposition.

Step-by-Step Solution

1

Analyze the histopathology of Minimal change disease.

Matches with diffuse effacement of podocyte foot processes.

It is the most common cause of pediatric nephrotic syndrome and lacks visible immune complex deposition.

2

Analyze the histopathology of Membranous nephropathy.

Matches with thickened capillary loops and subepithelial 'spike and dome' deposits.

Immune complexes deposit below the podocytes, prompting basement membrane material to grow up around them (spikes).

3

Analyze the histopathology of IgA nephropathy.

Matches with granular mesangial immune complex deposits.

IgA-based immune complexes specifically target and deposit within the mesangium, often following mucosal infections.

4

Analyze the histopathology of Goodpasture syndrome.

Matches with linear immunoglobulin deposition along the glomerular basement membrane.

Direct antibodies against the basement membrane (anti-GBM) coat the membrane smoothly, rather than in granular clumps.

Key Concept

Glomerular Disease Histopathology and Immunofluorescence Patterns

Estimated Time:1m 0s

Question 4511Question →

A $35$ -year-old man who recently emigrated from a country with high tuberculosis endemicity presents to the emergency department. He reports a $6$ -week history of a persistent, blood-tinged cough, subjective fevers, drenching night sweats, and a $6$ -kg ( $13$ -lb) weight loss. While in the crowded triage area, he is actively coughing. His vital signs show a temperature of $38.2^\circ\text{C}$ ( $100.8^\circ\text{F}$ ). Arrange the following steps in the most appropriate chronological order for the optimal management of this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of actions is to first establish airborne infection isolation, followed by initial diagnostic imaging with a chest radiograph, then obtaining definitive microbiological sputum samples, and finally initiating multidrug antituberculous therapy.

The management of suspected active pulmonary tuberculosis follows a strict chronological progression prioritizing public health, then diagnosis, then treatment. The immediate placement of a surgical mask and transfer to an airborne infection isolation room prevents nosocomial transmission. Once isolated, a chest radiograph serves as the initial diagnostic step to quickly evaluate for typical cavitary or infiltrative disease. Following this, consecutive sputum samples for AFB smear and culture must be obtained to confirm the diagnosis and secure isolates for susceptibility testing. Finally, a four-drug treatment regimen is initiated only after all diagnostic samples are successfully collected.

Step-by-Step Solution

1

Prioritize infection control by placing a mask on the patient and moving them to a negative-pressure isolation room.

Prevents the aerosolized spread of Mycobacterium tuberculosis to other patients and healthcare staff.

Airborne transmission risk is highest when an untreated patient is actively coughing in a shared space.

2

Perform initial diagnostic imaging with a chest radiograph.

Evaluates for classic signs of primary or reactivation tuberculosis, such as upper lobe infiltrates or cavitary lesions.

Provides rapid supportive evidence for the clinical suspicion before waiting for lengthy laboratory tests.

3

Collect

3

consecutive sputum samples for AFB smear and culture.

Secures the biological samples needed for definitive microbiological diagnosis and eventual drug susceptibility testing.

Samples must be collected prior to initiating antibiotics to ensure the highest diagnostic yield.

4

Initiate a four-drug empiric therapy regimen.

Begins the lengthy process of eradicating the mycobacterial infection.

Pharmacotherapy is the definitive treatment but should only be started after isolation and appropriate diagnostic sampling.

Key Concept

In patients with suspected active pulmonary tuberculosis, strict airborne infection control (masking and negative-pressure isolation) is the absolute first step in management, preceding all diagnostic testing and therapeutic interventions.

Estimated Time:45s

Question 4512Question →

A 45-year-old man with a history of intravenous drug use presents to the emergency department with a 1-week history of high fevers, chills, and profound fatigue. His temperature is 39.2°C (102.6°F), blood pressure is 110/70 mm Hg, and heart rate is 115/min. Physical examination is notable for a new early diastolic murmur heard best at the left lower sternal border, and painless erythematous macules on the palms of his hands. Laboratory results show a leukocyte count of 18,000/mm³ with a left shift. Arrange the following diagnostic and therapeutic steps in the most appropriate chronological order for managing this patient's acute presentation.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first obtain blood cultures, then initiate empiric antibiotics, followed by a transthoracic echocardiogram, and finally a transesophageal echocardiogram if needed.

The management of acute infective endocarditis requires rapid and sequential action. Blood cultures are the most critical diagnostic step and must be drawn first to ensure pathogen identification. Because acute endocarditis can be rapidly fatal, empiric broad-spectrum antibiotics must be started immediately following the blood draw, before imaging confirms the diagnosis. Once therapy is initiated, a transthoracic echocardiogram (TTE) is performed as the initial imaging modality due to its non-invasive nature and wide availability. If the TTE is negative or technically limited (which is common for small vegetations), a transesophageal echocardiogram (TEE) is the definitive next step due to its superior sensitivity.

Step-by-Step Solution

1

Identify the primary clinical syndrome.

The patient presents with fever, a new murmur (suggestive of aortic regurgitation), and Janeway lesions, which is highly suspicious for acute infective endocarditis.

Recognizing the acute, potentially life-threatening nature of the infection dictates the urgency of the management sequence.

2

Determine the first critical diagnostic intervention.

Multiple sets of blood cultures must be obtained before any other action.

Administering antibiotics prior to drawing cultures drastically reduces the chance of isolating the pathogen, which is required for tailoring targeted antimicrobial therapy.

3

Determine the timing of pharmacologic therapy.

Empiric antibiotics (e.g., vancomycin to cover MRSA) are administered immediately after cultures are drawn.

Delaying antimicrobial therapy in acute endocarditis can lead to rapid valvular destruction, heart failure, or severe septic embolization.

4

Sequence the imaging modalities.

TTE is ordered first, followed by TEE if the TTE is negative.

TTE is non-invasive and highly specific, making it the appropriate initial test. TEE is more invasive but more sensitive, used as a step-up diagnostic tool when initial imaging is indeterminate.

Key Concept

In patients with suspected acute infective endocarditis, the critical management sequence is to draw multiple blood cultures first, immediately start broad-spectrum empiric antibiotics, and then proceed with echocardiographic imaging (TTE followed by TEE if necessary).

Estimated Time:1m 30s

Question 4513Question →

A 68-year-old man is brought to the emergency department with 3 days of severe, watery diarrhea and poor oral intake. He reports feeling lightheaded upon standing. His temperature is $37.1^\circ$ C ( $98.8^\circ$ F), blood pressure is $112/72$ mm Hg supine and $90/60$ mm Hg standing, and pulse is 92/min supine and 116/min standing. Physical examination reveals dry mucous membranes and delayed capillary refill.

Laboratory results are as follows:

Serum studies:
Sodium: $140$ mEq/L
Potassium: $3.5$ mEq/L
Chloride: $110$ mEq/L
Bicarbonate: $20$ mEq/L
Blood urea nitrogen: $42$ mg/dL
Creatinine: $1.4$ mg/dL

Urine studies:
Sodium: $20$ mEq/L
Creatinine: $40$ mg/dL

Based on these findings, what is the patient's fractional excretion of sodium?

Show answer & explanation

Answer: 0.5

Answer

0.5

The correct calculation of the Fractional Excretion of Sodium (FENa) requires the formula:

FENa = \frac{U_{Na} \times P_{Cr}}{P_{Na} \times U_{Cr}} \times 100

. Plugging in the patient's values yields

(20 \times 1.4) / (140 \times 40) \times 100

, which simplifies to

28 / 5600 \times 100 = 0.5\%

. In the context of this patient's severe diarrhea, poor oral intake, and orthostatic hypotension, a FENa

< 1\%

accurately supports the diagnosis of a prerenal state (hypovolemia) with an appropriate, intact renal tubular reabsorption of sodium.

Step-by-Step Solution

1

Identify the formula for Fractional Excretion of Sodium (FENa).

FENa = \frac{U_{Na} \times P_{Cr}}{P_{Na} \times U_{Cr}} \times 100

This formula is used to differentiate prerenal acute kidney injury from intrinsic renal disease by measuring the fraction of filtered sodium that is excreted.

2

Substitute the patient's laboratory values into the equation.

U_{Na} = 20

mEq/L,

P_{Cr} = 1.4

mg/dL,

P_{Na} = 140

mEq/L,

U_{Cr} = 40

mg/dL

Accurate variable placement is required for correct calculation.

3

Calculate the final percentage.

(20 \times 1.4) / (140 \times 40) \times 100 = (28 / 5600) \times 100 = 0.5\%

Mathematical simplification yields the final FENa percentage.

Key Concept

Calculation of Fractional Excretion of Sodium (FENa)

Question 4514Question →

A 71-year-old man is evaluated in the intensive care unit regarding his antimicrobial regimen. He was admitted 12 days ago for acute respiratory distress syndrome secondary to a severe viral pneumonitis and required endotracheal intubation. Five days ago, his clinical status deteriorated with the development of a fever up to 39.4°C (102.9°F), worsening hypoxia, and thick, purulent endotracheal secretions. A chest radiograph at that time demonstrated a new dense consolidation in the left lower lobe. Empiric intravenous therapy with piperacillin-tazobactam, tobramycin, and vancomycin was initiated.

Today, the patient is clinically improving; he is afebrile (37.1°C [98.8°F]), and his ventilator settings have been significantly weaned. The quantitative bronchoalveolar lavage culture obtained five days ago exhibits heavy growth ( $10^5$ CFU/mL) of *Pseudomonas aeruginosa*. Antimicrobial susceptibility testing indicates the organism is susceptible to piperacillin-tazobactam, cefepime, and ciprofloxacin, but resistant to tobramycin. No other organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA), have been isolated. Blood cultures show no growth.

Which of the following is the most appropriate next step in this patient's pharmacotherapy?

Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapy

Discontinue vancomycin and substitute intravenous ciprofloxacin for tobramycin, while continuing piperacillin-tazobactam

Discontinue tobramycin, and continue piperacillin-tazobactam and vancomycin

Discontinue piperacillin-tazobactam, tobramycin, and vancomycin, and initiate meropenem monotherapy

Continue the current regimen of piperacillin-tazobactam, tobramycin, and vancomycin without modifications

Show answer & explanation

Answer: Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapy

Answer

Discontinue tobramycin and vancomycin, and continue piperacillin-tazobactam monotherapy.

The correct approach for this patient is to discontinue both tobramycin and vancomycin, continuing only piperacillin-tazobactam. The fundamental principle of antimicrobial stewardship in ventilator-associated pneumonia (VAP) is to initiate broad empiric therapy but de-escalate as soon as culture and susceptibility data are available. Because quantitative cultures did not yield MRSA, vancomycin must be stopped to reduce nephrotoxicity risk. Although empiric dual coverage for *Pseudomonas aeruginosa* (e.g., a beta-lactam plus an aminoglycoside) is appropriate to ensure initial activity against potentially resistant isolates, definitive therapy should be narrowed to a single active beta-lactam once susceptibilities are confirmed, provided the patient is not in septic shock. Piperacillin-tazobactam alone is fully active against this isolate and is sufficient for definitive cure.

Step-by-Step Solution

1

Evaluate the need for continued methicillin-resistant Staphylococcus aureus (MRSA) coverage.

The respiratory cultures did not grow MRSA.

Empiric MRSA coverage (vancomycin) should be discontinued if cultures are negative, in accordance with antimicrobial stewardship principles.

2

Assess the requirement for dual anti-pseudomonal therapy.

The patient's isolate is susceptible to piperacillin-tazobactam, and he is clinically improving.

Dual therapy is recommended for empiric coverage of suspected Pseudomonas infection to increase the likelihood of administering at least one active agent. Once susceptibilities are confirmed, definitive therapy with a single active beta-lactam is indicated.

3

Select the appropriate definitive regimen.

Discontinue tobramycin and vancomycin, retaining piperacillin-tazobactam.

Piperacillin-tazobactam provides adequate targeted monotherapy against this susceptible isolate while minimizing toxicity and resistance pressure.

Key Concept

In the management of ventilator-associated pneumonia, once pathogen susceptibilities are identified and the patient shows clinical improvement, empiric broad-spectrum therapy should be de-escalated. This includes stopping MRSA coverage if no MRSA is isolated and narrowing dual anti-pseudomonal therapy to a single active beta-lactam agent.

Question 4515Question →

A 58-year-old male is evaluated in the emergency department after his family noted progressive lethargy and confusion. According to his wife, he has experienced severe, nonbloody, bilious vomiting for the past five days. He has been unable to tolerate oral intake and has had minimal urine output for the past 24 hours. His medical history includes hypertension and untreated peptic ulcer disease. On physical examination, blood pressure is $88/54 \text{ mm Hg}$ , and pulse is $118/\text{min}$ . The patient appears lethargic. Mucous membranes are extremely dry, and skin turgor is significantly decreased.

Laboratory studies show the following:
Sodium: $140 \text{ mEq/L}$
Potassium: $3.2 \text{ mEq/L}$
Chloride: $90 \text{ mEq/L}$
Bicarbonate: $25 \text{ mEq/L}$
Blood urea nitrogen: $72 \text{ mg/dL}$
Creatinine: $3.4 \text{ mg/dL}$
Lactate: $6.2 \text{ mmol/L}$

Arterial blood gas (room air):
pH: $7.37$
$pCO_2$ : $45 \text{ mm Hg}$
$pO_2$ : $88 \text{ mm Hg}$

Which of the following best describes this patient's underlying acid-base derangements?

Mixed high anion gap metabolic acidosis and metabolic alkalosis

Mixed high anion gap metabolic acidosis and respiratory acidosis

Mixed normal anion gap metabolic acidosis and metabolic alkalosis

Pure high anion gap metabolic acidosis

Pure metabolic alkalosis

Show answer & explanation

Answer: Mixed high anion gap metabolic acidosis and metabolic alkalosis

Answer

Mixed high anion gap metabolic acidosis and metabolic alkalosis

This patient has a mixed high anion gap metabolic acidosis (HAGMA) and metabolic alkalosis. Despite a near-normal pH (

7.37

) and bicarbonate (

25 \text{ mEq/L}

), calculating the anion gap reveals a value of

25 \text{ mEq/L}

(

140 - [90 + 25]

), which confirms a HAGMA due to lactic acidosis (hypoperfusion) and uremia (acute kidney injury). To check for additional metabolic disorders, the delta-delta must be applied. The

\Delta AG

is

13

(

25 - 12

). In a pure HAGMA, the bicarbonate should drop by this same amount, resulting in an expected bicarbonate of

11 \text{ mEq/L}

(

24 - 13

). However, the patient's actual bicarbonate is

25 \text{ mEq/L}

. Because the actual bicarbonate is significantly higher than expected, there is a concurrent primary metabolic alkalosis, driven by the loss of gastric acid from severe vomiting. Finally, Winter's formula (

1.5 \times 25 + 8 \pm 2 = 45.5 \pm 2

) demonstrates that the patient's

pCO_2

of

45 \text{ mm Hg}

is appropriate compensation, ruling out any respiratory acid-base disorder.

Step-by-Step Solution

1

Calculate the Anion Gap (AG) to identify the presence of a primary metabolic acidosis.

AG = Na^+ - (Cl^- + HCO_3^-) = 140 - (90 + 25) = 25 \text{ mEq/L}

.

Always calculate the AG even if the pH and bicarbonate appear near-normal, as opposing disorders can mask the derangement.

2

Calculate the Delta Gap (

\Delta AG

) to determine how much the anion gap has risen above baseline.

\Delta AG = \text{Current AG} - \text{Normal AG} = 25 - 12 = 13 \text{ mEq/L}

.

This value represents the amount of unmeasured acid added to the blood, which should theoretically lower the bicarbonate by the same amount.

3

Calculate the expected bicarbonate if the high anion gap metabolic acidosis (HAGMA) were the only disorder.

\text{Expected } HCO_3^- = 24 - \Delta AG = 24 - 13 = 11 \text{ mEq/L}

. Since the actual

HCO_3^-

is

25 \text{ mEq/L}

, which is much higher than

11 \text{ mEq/L}

, a concurrent Metabolic Alkalosis is present.

Comparing expected to actual bicarbonate (the delta-delta method) unmasks hidden secondary metabolic disorders.

4

Assess respiratory compensation using Winter's formula based on the actual measured bicarbonate.

\text{Expected } pCO_2 = 1.5 \times (25) + 8 \pm 2 = 45.5 \pm 2 \text{ mm Hg}

. The actual

pCO_2

is

45 \text{ mm Hg}

, which falls within this range.

This confirms that there is no concurrent primary respiratory disorder; the respiratory status is perfectly compensated for the net bicarbonate level.

Key Concept

Delta-delta gap calculation unmasks hidden mixed acid-base disorders when opposing primary conditions (like lactic acidosis and vomiting) result in a deceptively normal pH or bicarbonate.

Estimated Time:2m 0s

Question 4516Question →

Match each of the following clinical vignettes describing neonatal respiratory distress to the most likely underlying diagnosis.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The vignettes correctly match as follows: The 28-week premature infant has Respiratory distress syndrome; the term infant born via C-section has Transient tachypnea of the newborn; the post-term infant with meconium has Meconium aspiration syndrome; and the infant with a scaphoid abdomen has a Congenital diaphragmatic hernia.

Each clinical scenario provides a classic triad of gestational age, risk factors, and chest radiograph findings that uniquely identify the primary causes of neonatal respiratory distress. Recognizing these distinct patterns is essential for appropriate diagnosis and management.

Step-by-Step Solution

1

Analyze the first vignette for key distinguishing features.

The patient is highly premature (28 weeks) with reticulogranular opacities, which points directly to surfactant deficiency.

Gestational age and specific radiographic findings are the primary differentiators in neonatal respiratory distress.

2

Evaluate the second vignette, focusing on the delivery method and imaging.

Term gestation with elective cesarean section and fluid in the interlobar fissures correlates with delayed fetal lung fluid clearance.

Lack of labor prevents the normal catecholamine surge that aids in fluid resorption, characteristic of transient tachypnea of the newborn.

3

Examine the third vignette for risk factors and radiographic signs.

A post-term infant with meconium exposure and patchy infiltrates indicates mechanical airway obstruction and chemical pneumonitis.

Meconium aspiration syndrome typically occurs in term or post-term infants who experience fetal distress.

4

Assess the fourth vignette for anatomical abnormalities.

A scaphoid abdomen and cystic structures in the chest indicate bowel herniation into the thoracic cavity.

Congenital diaphragmatic hernia causes pulmonary hypoplasia and severe respiratory distress, presenting with these classic physical and anatomical findings.

Key Concept

Differential diagnosis of neonatal respiratory distress based on gestational age, delivery history, physical exam, and radiographic findings.

Question 4517Question →

A 28-year-old woman, G1P0 at $30$ weeks gestation, comes to the clinic for a routine prenatal follow-up. She has a 5-year history of systemic lupus erythematosus (SLE) that has been quiescent on hydroxychloroquine. She reports mild, generalized fatigue and occasionally feeling "out of breath" when climbing stairs, but she explicitly denies joint pain, facial rashes, fevers, or chest pain. Her blood pressure is $112/70 \text{ mm Hg}$ , and her pulse is $85/\text{min}$ . Physical examination shows trace bilateral pedal edema but is otherwise unremarkable. Fetal heart tones are $145/\text{min}$ .

Laboratory studies show the following:

Test	Result
Hemoglobin	$10.2 \text{ g/dL}$
Leukocyte count	$11,500/\text{mm}^3$
Platelet count	$180,000/\text{mm}^3$
Serum creatinine	$0.6 \text{ mg/dL}$
Anti-dsDNA antibodies	Negative
Complement C3 and C4	Normal

Arterial blood gas analysis on room air reveals:

Parameter	Result
pH	$7.44$
PaCO $_2$	$28 \text{ mm Hg}$
HCO $_3^-$	$19 \text{ mEq/L}$

Urinalysis shows trace protein with no red blood cells or cellular casts. The patient is anxious and asks if her recent symptoms and laboratory abnormalities indicate that her autoimmune disease is worsening. Which of the following is the most appropriate next step in management?

Continuation of current management and reassurance

Initiation of high-dose oral prednisone therapy

Administration of oral sodium bicarbonate

Initiation of oral furosemide therapy

Initiation of empiric broad-spectrum antibiotic therapy

Show answer & explanation

Answer: Continuation of current management and reassurance

Answer

Continuation of current management and reassurance

The correct approach is to continue current management and provide reassurance. This patient's symptoms (mild fatigue, occasional dyspnea) and laboratory findings (hemoglobin of

10.2 \text{ g/dL}

, leukocyte count of

11,500/\text{mm}^3

, and a compensated respiratory alkalosis) are hallmark, normal physiologic adaptations to pregnancy. Her systemic lupus erythematosus (SLE) remains clinically and serologically inactive, as strongly evidenced by her normal complement levels, negative anti-dsDNA antibodies, and the absence of active urinary sediment (e.g., no red blood cell casts or significant proteinuria). Hydroxychloroquine is safe during pregnancy and is highly recommended to maintain disease remission and improve fetal outcomes.

Step-by-Step Solution

1

Evaluate the clinical presentation and laboratory findings in the context of the third trimester of pregnancy.

The patient exhibits mild fatigue, trace pedal edema, dilutional anemia (hemoglobin

10.2 \text{ g/dL}

), mild leukocytosis (

11,500/\text{mm}^3

), and a fully compensated respiratory alkalosis.

Pregnancy induces profound physiologic adaptations, including expanded plasma volume (causing dilutional anemia), progesterone-driven hyperventilation (causing chronic respiratory alkalosis with a compensatory drop in bicarbonate), and benign leukocytosis.

2

Assess the status of the patient's systemic lupus erythematosus (SLE) to rule out an acute disease flare.

The SLE is clinically and serologically quiescent. There are no active systemic symptoms, complement levels are normal, anti-dsDNA is negative, and the urinalysis is bland.

An active SLE flare in pregnancy would typically present with worsening proteinuria, hypertension, falling C3/C4 complement levels, and rising anti-dsDNA titers, none of which are present.

3

Determine the most appropriate management based on the findings.

The patient requires reassurance and continuation of her current hydroxychloroquine regimen.

Since all findings point to a normal, healthy pregnancy and well-controlled SLE, no acute interventions (such as steroids or diuretics) are indicated. Hydroxychloroquine should be maintained to prevent future flares.

Key Concept

Differentiating normal physiologic adaptations of pregnancy from acute systemic lupus erythematosus (SLE) flares

Question 4518Question →

An 11-day-old male newborn is brought to the pediatric clinic by his parents due to bilateral eye redness and discharge that began 2 days ago. The infant was born at 39 weeks of gestation via an uncomplicated, unassisted home birth to a 24-year-old mother who recently immigrated and did not receive prenatal care. He has been breastfeeding well and has normal wet diapers. Temperature is $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), pulse is 130/min, and respiratory rate is 40/min. Physical examination reveals bilateral hyperemic and edematous eyelids with a profuse mucopurulent exudate. The corneas appear clear, and there are no vesicles on the surrounding skin. A Gram stain of the conjunctival exudate reveals abundant leukocytes but no organisms. Which of the following is the most appropriate next step in management?

Intravenous cefotaxime

Topical erythromycin

Oral azithromycin

Intravenous acyclovir

Reassurance and warm compresses

Show answer & explanation

Answer: Oral azithromycin

Answer

Oral azithromycin

Oral azithromycin is the correct treatment. The infant's presentation at 11 days of life with mucopurulent conjunctivitis and a Gram stain showing leukocytes but no organisms is highly characteristic of Chlamydia trachomatis. Systemic macrolide therapy (such as oral azithromycin or erythromycin) is required to resolve the conjunctivitis, eradicate nasopharyngeal colonization, and prevent the development of chlamydial pneumonia.

Step-by-Step Solution

1

Identify the clinical presentation and timeline of the neonatal eye infection.

The infant has severe mucopurulent eye discharge beginning at 9 to 11 days of life.

The age of onset is the most critical factor in differentiating the etiologies of neonatal conjunctivitis (chemical is <24 hours, gonococcal is 2-5 days, chlamydial is 5-14 days).

2

Interpret the diagnostic Gram stain findings.

The Gram stain shows abundant leukocytes but no organisms.

Chlamydia trachomatis is an obligate intracellular bacterium that does not stain well with Gram stain, differentiating it from Neisseria gonorrhoeae which would clearly show Gram-negative intracellular diplococci.

3

Determine the appropriate therapeutic intervention.

Systemic therapy with a macrolide, such as oral azithromycin, is selected.

Systemic treatment is strictly necessary to eradicate the nasopharyngeal colonization of Chlamydia, which topical therapy cannot reach, thereby preventing the subsequent development of chlamydial pneumonia.

Key Concept

The diagnosis of neonatal chlamydial conjunctivitis relies on the timeline of presentation (5-14 days) and Gram stain findings (leukocytes without organisms), and it requires systemic macrolide therapy to prevent chlamydial pneumonia.

Estimated Time:1m 15s

Question 4519Question →

Match each clinical presentation with the most appropriate first-line targeted or empiric antimicrobial therapy.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The camper with wrist/ankle rash requires oral doxycycline (RMSF); the IV drug user with right-sided endocarditis requires intravenous vancomycin (MRSA); the college student with purpuric meningitis requires intravenous ceftriaxone (Meningococcus); and the farmer with broad-based budding yeast requires oral itraconazole (Blastomycosis).

Each pathogen or clinical syndrome has a highly specific first-line antimicrobial agent guided by local epidemiology, resistance patterns, and pharmacokinetics (such as CNS penetration for meningitis or intracellular activity for rickettsial disease).

Step-by-Step Solution

1

Analyze the tick-borne disease vignette.

Identify Rocky Mountain Spotted Fever based on the North Carolina location and centripetal petechial rash starting on extremities.

Recognizing the classic triad of fever, headache, and distal rash points directly to Rickettsia rickettsii, which must be treated with doxycycline.

2

Analyze the infective endocarditis vignette.

Identify right-sided (tricuspid) endocarditis complicated by septic pulmonary emboli in an intravenous drug user.

Staphylococcus aureus is the most common pathogen in this demographic, necessitating robust empiric MRSA coverage with vancomycin.

3

Analyze the central nervous system infection vignette.

Identify meningococcal meningitis based on the demographic (dormitory resident) and characteristic purpuric rash.

Neisseria meningitidis is a leading cause of bacterial meningitis in this age group and requires a third-generation cephalosporin like ceftriaxone for optimal CNS penetration and coverage.

4

Analyze the systemic fungal infection vignette.

Identify Blastomyces dermatitidis based on geography (Ohio), verrucous skin lesions, and broad-based budding yeast morphology.

Matching the morphologic description to the pathogen determines the choice of an azole antifungal, specifically itraconazole, for non-life-threatening systemic disease.

Key Concept

Selection of optimal empiric or targeted antimicrobial therapy based on clinical presentation, epidemiologic risk factors, and microbiological clues.

Question 4520Question →

An 8-year-old boy is evaluated in the pediatric clinic to establish care after his family recently moved from another state. He has a history of moderate persistent asthma. His current daily medications include a medium-dose fluticasone inhaler and a short-acting beta-agonist as needed. Three weeks ago, he was treated for an acute asthma exacerbation with a 4-day course of oral prednisone. He is currently asymptomatic and his lung examination is clear. Review of his medical record indicates he completed all routine immunizations up to age 2, but he missed the vaccine series typically given between ages 4 and 6 years (DTaP, IPV, MMR, and varicella). His father expresses concern about the safety of administering vaccines, particularly live vaccines, given the patient's asthma medications. Which of the following is the most appropriate action regarding this patient's immunizations today?

Administer the DTaP, IPV, MMR, and varicella vaccines today

Administer the DTaP and IPV vaccines today; schedule the MMR and varicella vaccines in one month

Administer the DTaP and IPV vaccines today; withhold the MMR and varicella vaccines while he requires inhaled corticosteroids

Delay all immunizations for one month due to his recent hospitalization for an asthma exacerbation

Administer the DTaP, IPV, and MMR vaccines today; withhold the varicella vaccine due to his history of reactive airway disease

Show answer & explanation

Answer: Administer the DTaP, IPV, MMR, and varicella vaccines today

Answer

Administer the DTaP, IPV, MMR, and varicella vaccines today.

The correct action is to administer the DTaP, IPV, MMR, and varicella vaccines today. This patient is due for his 4- to 6-year-old boosters. Live-attenuated vaccines (such as MMR and varicella) are contraindicated in severely immunocompromised patients, including those on high-dose systemic corticosteroids (defined as

\ge 2

mg/kg/day or

\ge 20

mg/day of prednisone for

14

or more days). However, short courses of systemic corticosteroids (less than

14

days) and the use of inhaled, topical, or intra-articular corticosteroids do not induce sufficient systemic immunosuppression to contraindicate live vaccines. Furthermore, the convalescent phase of a mild to moderate acute illness is not a reason to delay vaccination.

Step-by-Step Solution

1

Review the patient's immunization record and current age to determine which vaccines are due.

The patient is 8 years old and missed his 4- to 6-year-old boosters, so he is due for DTaP, IPV, MMR, and varicella vaccines.

Identifying missing vaccines is the first step in catch-up immunization scheduling.

2

Evaluate the patient's medical history for potential contraindications to live-attenuated vaccines (MMR and varicella).

The patient takes a daily inhaled corticosteroid and recently completed a 4-day course of oral prednisone.

Severe immunosuppression is an absolute contraindication to live-attenuated vaccines, and high-dose corticosteroid use must be evaluated.

3

Apply CDC immunization guidelines regarding corticosteroid use.

Guidelines state that inhaled corticosteroids and short courses of systemic corticosteroids (less than 14 days) do not cause sufficient immunosuppression to delay live vaccines.

Only high-dose systemic corticosteroids (

\ge 2

mg/kg/day or

\ge 20

mg/day of prednisone for

\ge 14

days) require a 1-month delay before live vaccine administration.

4

Determine the appropriate clinical intervention for today's visit.

Since there are no contraindications, all four indicated vaccines should be administered safely today.

Maximizing every clinical encounter to administer all eligible vaccines prevents further delays in care.

Key Concept

Short courses of systemic corticosteroids (less than 14 days) and inhaled corticosteroids are not contraindications to live-attenuated vaccines.

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept